ZELTIQ Announces Conference Call and Webcast of Second Quarter 2014 Financial Results to Be Held on July 29, 2014

ZELTIQ Announces Conference Call and Webcast of Second Quarter 2014 Financial 
Results to Be Held on July 29, 2014 
PLEASANTON, CA -- (Marketwired) -- 07/17/14 --  ZELTIQ(R) (NASDAQ:
ZLTQ), a medical technology company focused on developing and
commercializing products utilizing its proprietary controlled-cooling
technology platform, announced today that it plans to release its
second quarter 2014 financial results on Tuesday, July 29, 2014 after
the market close. 
ZELTIQ will hold a conference call on Tuesday, July 29, 2014 at 1:30
p.m. PT / 4:30 p.m. ET to discuss the results. The dial-in numbers
are (877) 280-7291 for domestic callers and (707) 287-9361 for
international callers. A live webcast of the conference call will be
available online from the investor relations page of the Company's
corporate website at www.coolsculpting.com. 
After the live webcast, the call will remain available on ZELTIQ's
website, www.coolsculpting.com, until ZELTIQ releases its third
quarter 2014 financial results. In addition, a telephonic replay of
the call will be available until August 5, 2014. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Please use the replay conference ID number
76290408. 
About ZELTIQ(R) Aesthetics, Inc. 
 ZELTIQ is a medical technology
company focused on developing and commercializing products utilizing
its proprietary controlled-cooling technology platform. ZELTIQ's
first commercial product, the CoolSculpting(R) System, is designed to
selectively reduce stubborn fat bulges. CoolSculpting is based on the
scientific principle that fat cells are more sensitive to cold than
the overlying skin and surrounding tissues. It utilizes patented
technology of precisely controlled cooling to reduce the temperature
of fat cells in the treated area, which is intended to cause fat cell
elimination through a natural biological process known as apoptosis.
ZELTIQ developed CoolSculpting to safely, noticeably, and measurably
reduce the fat layer. 
Investor Relations: 
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
925-474-2500 
Nick Laudico 
The Ruth Group
646-536-7030 
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.